ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Chordate Medical Holding AB's annualizedNet Income for the quarter that ended in Jun. 2025 was kr-20.77 Mil.
Chordate Medical Holding AB's average Total Assets over the quarter that ended in Jun. 2025 was kr22.19 Mil. Therefore, Chordate Medical Holding AB's annualized ROA % for the quarter that ended in Jun. 2025 was -93.60%.
The historical rank and industry rank for Chordate Medical Holding AB's ROA % or its related term are showing as below:
OSTO:CMH'
s ROA % Range Over the Past 10 Years
Min: -143.79 Med: -84.03 Max: -30.9
Current: -117.69
During the past 10 years, Chordate Medical Holding AB's highest ROA % was -30.90%. The lowest was -143.79%. And the median was -84.03%.
OSTO:CMH's ROA % is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 0.545
vs OSTO:CMH: -117.69
Chordate Medical Holding AB (OSTO:CMH) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Jun. 2025) net income data. The Revenue data used here is four times the quarterly (Jun. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Chordate Medical Holding AB's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chordate Medical Holding AB ROA % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Chordate Medical Holding AB's ROA % distribution charts can be found below:
* The bar in red indicates where Chordate Medical Holding AB's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Chordate Medical Holding AB (OSTO:CMH) has a ROA % of -93.60% as of Jun. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Chordate Medical Holding AB and its competitors.
Is Chordate Medical Holding AB's ROA % too high?
Chordate Medical Holding AB's current ROA % is -93.60%. Overall, Chordate Medical Holding AB has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Chordate Medical Holding AB's ROA % compare to ABT and SYK?
Chordate Medical Holding AB's ROA % of -93.60% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROA % is 0.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Devices & Instruments company?
The median ROA % among Medical Devices & Instruments companies is 0.55, based on 858 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Chordate Medical Holding AB and its competitors. For the Medical Devices & Instruments industry, the median ROA % is 0.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chordate Medical Holding AB's current ROA % is -93.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chordate Medical Holding AB stock overvalued right now?
Chordate Medical Holding AB (OSTO:CMH) has a current ROA % of -93.60%. The stock's GF Value™ is kr26.18, compared to a current price of kr0.16 — trading 99.4% below its estimated fair value. The current ROA % is -93.60%. Chordate Medical Holding AB's overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Chordate Medical Holding AB (OSTO:CMH), the current ROA % is -93.60% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chordate Medical Holding AB (OSTO:CMH) Overvalued in 2026?
Based on GuruFocus' analysis, Chordate Medical Holding AB stock appears to be undervalued.
The current stock price of kr0.16 is trading 99.4% below its estimated GF Value™ of kr26.18.
Key valuation signals for OSTO:CMH:
ROA %: -93.60%
GF Value™: kr26.18 vs. price of kr0.16 (99.4% below fair value)
No single metric tells the full story. See the OSTO:CMH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chordate Medical Holding AB is a medical technology company that has developed patented and CE-marked a new nerve-modulating treatment technology for chronic nasal congestion and chronic migraine. The company sells its products in Selected European markets, Israel, and Saudi Arabia. The company's product range is based on the CE-marked treatment units Chordate System S100 and S120 for rhinitis and S220 for migraine, registered for the indications of preventive treatment of chronic migraine and chronic rhinitis and use on patients. The company sells its product system, including treatments, through distributors to clinics and hospitals in its primary markets.
46GF Score
Get the complete analysis for OSTO:CMH
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:CMH has been successfully added to your 
